

Datasheet: MCA1784F BATCH NUMBER 1711

Description:	RAT ANTI HUMAN EGF RECEPTOR:FITC		
Specificity:	EGF R		
Other names:	EPIDERMAL GROWTH FACTOR RECEPTOR		
Format:	FITC		
Product Type:	Monoclonal Antibody		
Clone:	ICR10		
Isotype:	lgG2a		
Quantity:	0.1 mg		

Product Details

Applications	This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further					
	information. For general protocol recommendations, please visit <u>www.bio-</u>					
	rad-antibodies.com/pro	tocols.				
	Flow Outomotine	Yes No	Not Determined	Suggested Dilution		
	Flow Cytometry			1/10		
	Where this antibody han necessarily exclude its the antibody for use in	s not been tested f use in such procec their own system u	or use in a particular lures. It is recommen sing appropriate nega	technique this does not ded that the user titrates ative/positive controls.		
Target Species	Human					
Product Form	Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid					
Max Ex/Em	Fluorophore	Excitation Max (nm) Emission Max (nm)		
	FITC	490	525			
Preparation	Purified IgG prepared by ion exchange chromatography					
Buffer Solution	Phosphate buffered saline					
Preservative	0.09% Sodium Azide					
Stabilisers	1% Bovine Serum Albumin					
Approx. Protein Concentrations	IgG concentration 0.1 mg/ml					

External Database Links	UniProt: P00533 Related reagents Entrez Gene: 1956 EGFR Related reagents
Synonyms	ERBB1
RRID	AB_324284
Specificity	Rat anti Human EGF Receptor antibody, clone ICR10 recognizes the human epidermal growth factor receptor (EGF-R), which is over expressed in a high proportion of breast cancer cells and in a range of other carcinomas.
	High level expression of EGFR is often associated with advanced disease and poor prognosis.
	Rat anti Human EGF Receptor antibody, clone ICR10 binds to epitope B from EGFR (<u>Lottaz <i>et al.</i> 2010</u> and <u>Moditahedi <i>et al.</i> 1993</u>) and has an affinity of 6.7 x 10^{-9} M.
Flow Cytometry	Use 10ul of the suggested working dilution to label 10 ⁶ cells in 100ul.
References	 Lottaz,C. <i>et al.</i> (2010) Transcriptional Profiles of CD133+ and CD133- Glioblastoma- Derived Cancer Stem Cell Lines Suggest Different Cells of Origin <u>Cancer Res. 70</u>: 2030-40. Modjtahedi, H. <i>et al.</i> (1993) Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor. <u>Cell</u> <u>Biophys. 22 (1-3): 129-46.</u> Modjtahedi, H. <i>et al.</i> (2012) Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. <u>Br J</u> <u>Cancer. 106 (5): 883-8.</u> Grinberg, O. <i>et al.</i> (2013) Antibody modified Bovine Serum Albumin microspheres for targeted delivery of anticancer agent Gemcitabine <u>Polymers for Advanced Technologies.</u> 24 (3): 294-299. Gilcrease, M.Z. <i>et al.</i> (2009) Alpha6beta4 integrin crosslinking induces EGFR clustering and promotes EGF-mediated Rho activation in breast cancer. <u>J Exp Clin Cancer Res. 28</u>: <u>67.</u> Tilburgs, T. <i>et al.</i> (2015) Human HLA-G+ extravillous trophoblasts: Immune-activating cells that interact with decidual leukocytes. <u>Proc Natl Acad Sci U S A. 112 (23): 7219-24.</u> Tilburgs, T. <i>et al.</i> (2015) The HLA-G cycle provides for both NK tolerance and immunity at the maternal-fetal interface. <u>Proc Natl Acad Sci U S A. 112 (43): 13312-7.</u> Khelwatty, S.A. <i>et al.</i> (2015) Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. <u>Br J Cancer. 113 (7): 1010-9.</u>

Storage	Store at +4°C or at -20°C if preferred.
	This product should be stored undiluted.
	Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
	Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch
Health And Safety Information	Material Safety Datasheet documentation #10041 available at: https://www.bio-rad-antibodies.com/SDS/MCA1784F 10041
Regulatory	For research purposes only

Related Products

Recommended Negative Controls

RAT IgG2a NEGATIVE CONTROL:FITC (MCA6005F)

Recommended Useful Reagents

HUMAN SEROBLOCK (BUF070A) HUMAN SEROBLOCK (BUF070B)

North & South	Tel: +1 800 265 7376	Worldwide	Tel: +44 (0)1865 852 700	Europe	Tel: +49 (0) 89 8090 95 21
America	Fax: +1 919 878 3751		Fax: +44 (0)1865 852 739		Fax: +49 (0) 89 8090 95 50
	Email: antibody_sales_us@bio	o-rad.com	Email: antibody_sales_uk@bic	o-rad.com	Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M365735:200529'

Printed on 22 Mar 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint